Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

To join this study, you would generally need to be an adult with a good level of physical fitness, able to handle daily activities with little difficulty. Your doctors would need to be able to measure your cancer on scans, and you would need at least one area of your cancer that can be injected. We would also need to look at a sample of your cancer tissue, either from a past biopsy or a new one.

This study is for people whose cancer has already been treated with other medicines, especially a type of treatment called anti-PD1/PD-L1 therapy, and your cancer has either continued to grow or come back. This includes specific types of non-melanoma skin cancer, melanoma, non-small cell lung cancer, and certain solid tumours with the MSI-H genetic marker. You should also be expected to live for at least another three months.

However, you couldn't join if you've already had a similar virus-based treatment (oncolytic therapy). You also can't participate if you have certain past or current health issues, such as a history of severe viral infections (especially certain herpes infections), serious heart problems, or certain lung conditions. Regular use of anti-viral medications or uncontrolled spread of cancer to the brain would also prevent you from joining.

If you decide to join this study, you would receive the study medication, RP1, which might be given alone or with nivolumab. These medicines are typically given as injections or infusions. You would have regular visits to the clinic for treatments, health checks, blood tests, and scans to monitor your cancer and how you're feeling. Doctors would check for any side effects and see how your body is responding to the treatment. The total duration of your participation would depend on how your body responds to the treatment and the study's protocol, but it would involve ongoing check-ups. You would also need to provide tissue samples for further analysis.